Glioblastoma

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

The FDA awarded 11 grants worth more than $25 million to fund clinical trials of medical products intended to treat patients with rare diseases.

The FDA granted breakthrough device designation to Alpha DaRT for treatment of recurrent glioblastoma multiforme.

Inspired by the death of then-Vice President Joe Biden’s son, Beau, due to glioblastoma, the NCI launched the Cancer Moonshot in 2016 with the goal of advancing cancer research and treatment.

The FDA granted orphan drug designation to LP-184 for the treatment of glioblastoma multiforme and other malignant gliomas.

Neuro-oncologists must grapple daily with precarious brain tumors that are often masked by common symptoms such as a headache or seizure.

The FDA granted orphan drug designation to iniparib for treatment of malignant glioma, according to the agent’s manufacturer.

The FDA granted fast track designation to berubicin for the treatment of recurrent glioblastoma multiforme, according to the agent’s manufacturer.

Chimeric antigen receptor T cells have emerged “as a promising therapeutic avenue” for the treatment of glioblastoma, though various factors still limit its efficacy, according to a review published in Neurology.